0001193125-26-131872
SEC filingAssembly Biosciences approved the 2026 Corporate Bonus Plan and increased CEO Jason A. Okazaki's bonus target from 60% to 65% of base salary, effective for fiscal year 2026.
The approval of the 2026 Corporate Bonus Plan establishes a structured incentive framework tying employee compensation to corporate performance metrics approved by the Board and individual goals, with varying weights by role—100% corporate for the CEO, down to 25% for associate directors and below. This aligns executive pay directly with company-wide financial and operational achievements, potentially driving focus on key milestones. The specific increase in CEO Jason A. Okazaki's target bonus to 65% of base salary reflects committee confidence in his leadership amid the new plan's rollout, with actual payouts determined post-performance period review and capped at 1.5x target if employed through payment.